Sp1060
OPTIMAL APPROACHES FOR MEASURING BARRIER DYSFUNCTION IN FGID/DGBI: ARE WE READY FOR PRIME TIME?
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology. Speakers will cover investigational and evolving biomarkers, practical utilization of biomarkers, and updates on biomarkers that are further down the pipeline and may be available for broader use in clinical practice and clinical research. Discuss novel and investigational biomarkers in functional gastrointestinal disorders (disorders of gut-brain interaction) Recognize currently available biomarkers and their potential applications in clinical practice, their strengths, and their limitations. Review the path to biomarker discovery and their role in enhancing patient care, highlighting challenges and future goals.
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology. Speakers will cover investigational and evolving biomarkers, practical utilization of biomarkers, and updates on biomarkers that are further down the pipeline and may be available for broader use in clinical practice and clinical research. Discuss novel and investigational biomarkers in functional gastrointestinal disorders (disorders of gut-brain interaction) Recognize currently available biomarkers and their potential applications in clinical practice, their strengths, and their limitations. Review the path to biomarker discovery and their role in enhancing patient care, highlighting challenges and future goals.
Presenter
Mayo Clinic
Tracks
Related Products
CHANGES TO GASTRIC TISSUE RESIDENT MUSCULARIS MACROPHAGES PHENOTYPE FOLLOWING THE ONSET OF DIABETES
This session will focus on intercellular signaling mechanisms between neurons and non-neuronal cells that control gut motor functions…
Q&A
Disorders of gut-brain interaction (DGBI), including irritable bowel syndrome (IBS) and functional dyspepsia (FD), are among the most common gastrointestinal (GI) disorders seen in primary care and GI practices. The pathophysiology is multifactorial and not well understood…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
MECHANISTIC EVIDENCE FOR ALTERED INTESTINAL PERMEABILITY IN FOOD SENSITIVITIES, FUNCTIONAL DYSPEPSIA AND IBS
Disorders of gut-brain interaction (DGBI), including irritable bowel syndrome (IBS) and functional dyspepsia (FD), are among the most common gastrointestinal (GI) disorders seen in primary care and GI practices. The pathophysiology is multifactorial and not well understood…
